Compare Crispr Therapeutics AG (CRSP) vs Newegg Commerce Inc (NEGG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Newegg Commerce Inc — how do they compare? Crispr Therapeutics AG trades at $50.33 (market cap $4.97B), while Newegg Commerce Inc trades at $14.1 (market cap $295.52M). The key difference: Crispr Therapeutics AG is far larger — about 16.8× Newegg Commerce Inc's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Newegg Commerce Inc nearer its low. Which is the better fit depends on your goals.
| CRSP | NEGG | |
|---|---|---|
Market Cap | $4.97B | $295.52M |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $128.09 |
52-Week Low | $44.34 | $13.87 |
Enterprise Value | $3.32B | $294.32M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
NEGG trades at $13.87, down 1.98% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $4.88 million for 2025, though revenue improved to $1.44 billion. Recent news highlights AI shopping initiatives and the FantasTech sale, indicating ongoing business development efforts. Cash flow from operations remains negative at -$26.97 million, but financing activities provided a net cash inflow of $8.91 million.
The outlook is mixed; a single analyst rates NEGG a buy, and profitability may recover by 2026. However, persistent operating losses, weak cash generation, and high debt-to-asset ratios pose significant risks. Investors should weigh potential e-commerce growth against fundamental weaknesses and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Newegg Commerce Inc
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →
